2. Academic Validation
  3. Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline

Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline

  • Lancet Child Adolesc Health. 2020 Feb;4(2):141-150. doi: 10.1016/S2352-4642(19)30336-0.
David R Freyer 1,  Penelope R Brock 2,  Kay W Chang 3,  L Lee Dupuis 4,  Sidnei Epelman 5,  Kristin Knight 6,  Denise Mills 7,  Robert Phillips 8,  Emma Potter 9,  Demie Risby 10,  Philippa Simpkin 11,  Michael Sullivan 12,  Sandra Cabral 13,  Paula D Robinson 13,  Lillian Sung 14
Affiliations

Affiliations

  • 1 Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA; Departments of Pediatrics and Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, US.
  • 2 Department of Haematology and Oncology, Great Ormond Street Hospital, London, UK.
  • 3 Department of Otolaryngology-Head and Neck Surgery, Stanford University, Palo Alto, CA, USA.
  • 4 Department of Pharmacy, The Hospital for Sick Children, Toronto, ON, Canada; Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
  • 5 Department of Pediatric Oncology, Casa de Saude Santa Marcelina, Sao Paolo, Brazil.
  • 6 Pediatric Audiology, Doernbecher Children's Hospital, Oregon Health and Science University, Portland, OR, USA.
  • 7 Division of Haematology and Oncology, The Hospital for Sick Children, Toronto, ON, Canada; Pediatric Oncology Group of Ontario, Toronto, ON, Canada.
  • 8 Department of Haematology and Oncology, Leeds Teaching Hospital, NHS Trust, Leeds, UK; Centre for Reviews and Dissemination, University of York, York, UK.
  • 9 Division of Oncology, Royal Marsden Hospital, London, UK.
  • 10 Great Ormond Street Hospital, London, UK.
  • 11 London, UK.
  • 12 Children's Cancer Centre, Royal Children's Hospital, Melbourne, VIC, Australia; Department of Paediatrics, Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia.
  • 13 Pediatric Oncology Group of Ontario, Toronto, ON, Canada.
  • 14 Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada; Division of Haematology and Oncology, The Hospital for Sick Children, Toronto, ON, Canada. Electronic address: lillian.sung@sickkids.ca.
PMID: 31866182 DOI: 10.1016/S2352-4642(19)30336-0
Abstract

Despite ototoxicity being a prevalent consequence of cisplatin chemotherapy, little guidance exists on interventions to prevent this permanent and progressive adverse event. To develop a clinical practice guideline for the prevention of cisplatin-induced ototoxicity in children and adolescents with Cancer, we convened an international, multidisciplinary panel of experts and patient advocates to update a systematic review of randomised trials for the prevention of cisplatin-induced ototoxicity. The systematic review identified 27 eligible adult and paediatric trials that evaluated amifostine, sodium diethyldithiocarbamate or disulfiram, systemic sodium thiosulfate, intratympanic therapies, and cisplatin infusion duration. Regarding systemic sodium thiosulfate, the panel made a strong recommendation for administration in non-metastatic hepatoblastoma, a weak recommendation for administration in Other non-metastatic cancers, and a weak recommendation against its routine use in metastatic cancers. Amifostine, sodium diethyldithiocarbamate, and intratympanic therapy should not be routinely used. Cisplatin infusion duration should not be altered as a means to reduce ototoxicity. Further research to determine the safety of sodium thiosulfate in patients with metastatic Cancer is encouraged.

Figures
Products